相关实验视频

Updated: Jul 17, 2025

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

发现了第一种具有强烈的体外抗繁殖活性的新型sigma/HDACi双联体

Carla Barbaraci¹, Viviana di Giacomo², Annalisa Maruca³

¹Department of Drug and Health Sciences, Medicinal Chemistry Section, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.

Bioorganic chemistry

|September 2, 2023

概括

研究人员开发了用于癌症治疗的新型双抑制剂. 化合物6作为一种具有平衡西格玛受体和HDAC抑制的抗增殖剂具有前景,为复杂疾病提供了一种新方法.

科学领域:

药用化学医学化学
药理学药理学是指药理学的学科.
在瘤学瘤学.

背景情况:

开发双位抑制剂为制造更安全,更有效的癌症药物带来了挑战.
同时的目标调节可能会改善患者的服药性,减少药物耐药性.

研究的目的:

设计和合成针对西格玛受体 (σR) 和胰岛素脱乙酶抑制剂 (HDACi) 的新型双联体.
评估这些化合物作为治疗癌症等复杂疾病的潜在创新候选者.

主要方法:

针对 σR 和 HDAC 的新型双联体的合成.
对各种瘤细胞系进行合成化合物的查.
分子对接研究以确认目标亲和力和结合方式.

主要成果:

化合物6对HCT116癌细胞表现出显著的抗增殖活性 (IC50 = 0.9μM).
化合物6表现出对西格玛受体 (K_iσ₁R = 38 ± 3.7 nM) 和HDACs (IC₅₀ = 0.59 μM) 的强烈抑制.
在正常细胞中没有观察到显著的毒性,分子对接证实了对两个目标的平衡亲和力.

结论:

化合物6是一种有前途的抗增殖剂,具有双重 σR / HDACi活性.
这种双重准策略为癌症治疗提供了潜在的新途径.
需要进一步的研究,以探索其在复杂疾病中的治疗潜力.

关键词:

癌症癌症癌症癌症双联体体是双联体体的这是一种HDAC酶.多因素性疾病是多因素性疾病.σ(1) 接收器接收器

更多相关视频

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...